Evidence map›Paper›PMID 28465300›Full record

Trial reportJournal of the American Heart Association2017

Randomized Trial Comparing the Effects of Ticagrelor Versus Clopidogrel on Myocardial Perfusion in Patients With Coronary Artery Disease.

Matthieu Pelletier-Galarneau, Chad R R N Hunter, Kathryn J Ascah, Rob S B Beanlands, Girish Dwivedi, Robert A deKemp, Benjamin J W Chow, Terrence D Ruddy

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase IIComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Heart Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01894789 (ComPArison of the Effect of Ticagrelor Versus Clopidogrel on Myocardial Blood Flow), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01894789 phase2 / phase3completednot on this map

ComPArison of the Effect of Ticagrelor Versus Clopidogrel on Myocardial Blood Flow (MBF) and Reserve (MBFR) Measured With Positron Emission TomograpHy (PET) in Patients With Coronary Artery Disease (CAD): The PATH Study

TypeinterventionalSponsorOttawa Heart Institute Research CorporationRan2013 to 2015Enrolled36ConditionsCoronary Artery DiseaseArmsTicagrelor, Clopidogrel
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. A Review of the Role of the Antiplatelet Drug Ticagrelor in the Management of Acute Coronary Syndrome, Acute Thrombotic Disease, and Other Diseases.Medical science monitor : international medical journal of experimental and clinical research · 2022
    Review
  3. The potential of regional myocardial blood flow measurement with SPECT.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021
    Article
  4. Assessing therapeutic efficacy in coronary artery disease with SPECT myocardial blood flow.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2020
    Article
  5. The potential for PET-guided revascularization of coronary artery disease.European journal of nuclear medicine and molecular imaging · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Matthieu Pelletier-GalarneauDivision of Nuclear Medicine, The Ottawa Hospital, Ottawa, Canada.
Chad R R N HunterDepartment of Medicine, University of Ottawa, Canada.
Kathryn J AscahDepartment of Medicine, University of Ottawa, Canada.
Rob S B BeanlandsDepartment of Medicine, University of Ottawa, Canada.
Girish DwivediDepartment of Medicine, University of Ottawa, Canada.
Robert A deKempDepartment of Medicine, University of Ottawa, Canada.
Benjamin J W ChowDepartment of Medicine, University of Ottawa, Canada.
Terrence D RuddyDivision of Nuclear Medicine, The Ottawa Hospital, Ottawa, Canada truddy@ottawaheart.ca.
University of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTicagrelor is a P2Y METHODS AND

resultsThis randomized double-blinded crossover study included 22 patients who received therapeutic interventions of ticagrelor 90 mg orally twice a day for 10 days and clopidogrel 75 mg orally once a day for 10 days, with a washout period of at least 10 days between the treatments. Global and regional MBF and myocardial flow reserve were measured using rubidium 82 positron emission tomography/computed tomography at baseline and during intermediate- and high-dose adenosine. Global MBF was significantly greater with ticagrelor versus clopidogrel (1.28±0.55 versus 1.13±0.47 mL/min per gram,

conclusionsTicagrelor potentiates global and regional adenosine-induced MBF increases in patients with stable coronary artery disease. This effect may contribute to the incremental mortality benefit compared with clopidogrel. CLINICAL

trial registrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT01894789.

Indexed as

AdenosineAdministration, OralAgedClopidogrelCoronary Artery DiseaseCoronary CirculationCoronary VesselsCross-Over StudiesDouble-Blind MethodDrug Administration ScheduleFemaleHumansMaleMiddle AgedMyocardial Perfusion ImagingOntarioAdenosineClopidogrelPlatelet Aggregation InhibitorsRadiopharmaceuticalsRubidium RadioisotopesTicagrelorTiclopidineVasodilator Agentsadenosineclopidogrelmyocardial blood flowpositron emission tomographyticagrelor

Identifiers

PMID28465300
PMCPMC5524115
OpenAlexW2610939032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.